← Eichor
Study identifier: NCT05588700 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients

Condition: Metastatic Testicular Cancer  ·  Sponsor: Centre Leon Berard

PhaseNA
Planned participants236
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Testicular germ cell tumor (TGCT) is the most common malignancy in men between 15 and 40 years. Although TCGT survivors have a good survival prognosis, they suffer from short- and long-term sequelae such as chronic fatigue, psychological disorders, cardiovascular toxicities and second malignancies. The benefits of physical activity (PA) during treatments have been demonstrated in cancer patients to improve quality of life (QoL) and physical fitness and to reduce fatigue. However, few PA programs have been proposed to TGCT patients and their effects on sequelae have not been assessed yet. A growing body of evidence links treatment-related alteration in the gut microbiota to sequelae of cancer survivors, including fatigue and cardiovascular toxicities. Also, PA has been known as a possible modulator of the gut microbiota composition. To date, no study has been conducted to examine how the gut microbiota and its metabolites moderate the effect of PA on fatigue and other late effects in TGCT survivors. The objectives will be to assess the impact of a PA program on fatigue and other sequelae and to investigate how the gut microbiota and its metabolites moderate the associations between PA and sequelae. We will conduct a prospective, multicenter, phase III, randomized controlled trial of a one-year supervised PA program. 236 men with metastatic TGCT and eligible for a first line of chemotherapy will be randomly assigned to either PA intervention or control arm. All patients will be…

This description comes directly from the study's public registry record.

Talk to the study team

Carmen Dupuis, PhD  ·  0469856218  ·  carmen.dupuis@lyon.unicancer.fr

Olivia Pérol, PhD  ·  0478782897  ·  olivia.perol@lyon.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (12)

Institut de Cancérologie de LorraineAngers, FranceNot Yet Recruiting
CHU Jean MinjozBesançon, FranceNot Yet Recruiting
Institut BergoniéBordeaux, FranceNot Yet Recruiting
Centre François BaclesseCaen, FranceNot Yet Recruiting
Centre Oscar LambretLille, FranceNot Yet Recruiting
Centre Leon BerardLyon, FranceRecruiting
Institut de Cancérologie de LorraineNancy, FranceRecruiting
Centre Antoine LacassagneNice, FranceNot Yet Recruiting
AP-HP TenonParis, FranceNot Yet Recruiting
Centre Eugène MarquisRennes, FranceNot Yet Recruiting
CHU ToursTours, FranceNot Yet Recruiting
Institut Gustave RoussyVillejuif, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05588700